The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
Abstract
BACKGROUND Frequent anti-vascular endothelial growth factor A (VEGF-A) injections reduce the risk of rapid and severe vision loss in patients with neovascular age-related macular degeneration (nAMD); however, due to undertreatment, many patients lose vision over time. New treatments that provide sustained suppression of VEGF-A are needed. RGX-314 (currently known as ABBV-RGX-314) is an adeno-associated virus serotype 8 vector that expresses an anti-VEGF-A antigen-binding fragment, which provides potential for continuous VEGF-A suppression after a single subretinal injection. We report results on the safety and efficacy of subretinal injection of RGX-314 in patients with nAMD. METHODS For this open-label, multiple-cohort, multicentre, phase 1/2a, dose-escalation study conducted at eight sites in the USA, we enrolled participants with nAMD aged 50-89 years who had previously been treated with anti-VEGF injections into five cohorts (with five different doses of RGX-314). To be eligible, participants had to have macular neovascularisation secondary to nAMD with subretinal or intraretinal fluid in the centre subfield, be pseudophakic (after cataract removal), and have a best-corrected visual acuity (BCVA) in the study eye between 20/63 and 20/400 for the first participant in each cohort and between 20/40 and 20/400 for others. Subretinal injection of RGX-314 was done without a pre-bleb by a wet-laboratory-trained vitreoretinal surgeon. Cohort 1 received 3 × 109 genome copies per e…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cre ation of biofactories in the eye is a strategy that has thus far relied on either intravitreal (Heier et al., 2017) or single-site subretinal injection (Rakoczy et al., 2015; Campochiaro et al., 2024).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Campochiaro et al., 2024
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationWong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Self-citationMaguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708
Self-citationHolz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Cortez, R., Hoyng, C. B., Hykin, P., Staurenghi, G., Heldner, S., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305327 · Cited by 615
Campochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.167 · Cited by 343
Self-citationCukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Cited by
Different Therapeutic Approaches for Dry and Wet AMD
Marchesi, N., Capierri, M., Pascale, A., & Barbieri, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313053 · Cited by 68
Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration
Vujosevic, S., Lupidi, M., Donati, S., Astarita, C., Gallinaro, V., & Pilotto, E. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.07.006 · Cited by 54
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 49
Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases
Liu, H., Huang, S. S., Gopal, L., Kai, D., Su, X., & Liu, Z. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04007-5 · Cited by 47
Metadata
- Authors
- Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., Wykoff, C. C., & Van Everen, S.
- Affiliations
- Johns Hopkins University (US)
- California Retina Consultants (US)
- Retina Consultants of Texas (US)
- Ophthalmic Consultants of Boston (US)
- Thomas Jefferson University (US)
- University of Tennessee Health Science Center (US)
- Duke University (US)
- Sierra Eye Associates (US)
- Regenxbio (United States) (US)
- Corresponding author
- Campochiaro, Peter A
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 403
- Issue
- 10436
- Pages
- 1563-1573
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4393238641
- Cited by
- 135
- References
- 18
- Citations by year
- 2026: 53 · 2025: 58 · 2024: 24
- FWCI
- 53.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- REGENXBIO Inc
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, gene therapy, subretinal injection, AAV8, dose escalation, safety, visual acuity, retinal neovascularization
- MeSH terms
- Ranibizumab, Humans, Genetic Therapy, Treatment Outcome, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00310-6
- The paper
- Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., Wykoff, C. C., & Van Everen, S. (2024). Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. The Lancet. https://doi.org/10.1016/s0140-6736(24)00310-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.